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Abstract  
 
(i) Rationale, aims and objectives:  Underuse of anticoagulants in atrial fibrillation is 
known to increase the risk of stroke and is an international problem.  The National 
Institute for Health Care and Excellence guidance CG180 seeks to reduce atrial 
fibrillation related strokes through prescriptions of Non-vitamin K antagonist Oral 
Anticoagulants.  A quality improvement programme was established by the West of 
England Academic Health Science Network (West of England AHSN) to implement 
this guidance into General Practice.  
 
A realist evaluation identified whether the quality improvement programme worked, 
determining how and in what circumstances.  This realist evaluation tested the 
programme theory through careful, systematic consideration of the General Practice 
context, the training and support mechanisms provided through the quality 
improvement team and reviewed the outcome changes in the practice.   
 
(ii) Methods: Six General Practices in one region, became the case study sites. 
Quality improvement team, doctor and pharmacist meetings within each of the 
General Practices were recorded at three stages: initial planning, review and final. 
Additionally, 15 interviews conducted with the practice leads, explored experiences 
of the quality improvement process. Observation and interview data were analysed, 
and compared against the initial programme theory. 
 
(iii) Results: The quality improvement resources available were used variably, with 
the training being valued by all.  The initial programme theories were refined 
following the data collection and analysis. In particular, local workload pressures and 
individual General Practitioner experiences and pre-conceived ideas were 
acknowledged. Where key motivators were in place, such as prior experience and a 
commitment to quality improvement and evidence-based care delivery, the 
programme achieved optimal outcomes and secured a lasting quality improvement 
legacy. 
 
(iv) Conclusion: The employment of a quality improvement programme can deliver 
practice change and improvement legacy outcomes when particular mechanisms are 
employed and in contexts where there is a commitment to improve service.  
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Introduction  
 
Atrial Fibrillation (AF) is a chronic condition affecting around one million people in 
the UK and involves a significantly increased risk of stroke.  Atrial Fibrillation related 
strokes are more likely to be fatal or cause severe disability1. National Institute for 
Health Care and Excellence (NICE) guidance CG1802 recommends Non-vitamin K 
antagonist Oral Anticoagulants (NOACs) as equal first-line options alongside 
warfarin. These guidelines suggest that antiplatelet agents (aspirin) should not be 
used as monotherapy to prevent non-valvular atrial fibrillation-related stroke.  
 
A report by the Association of the British Pharmaceutical Industry, Stroke in Atrial 
Fibrillation Initiative 3 found that despite the guidance the uptake of NOACs has been 
lower and slower than the National Institute for Health Care and Excellence   
anticipated and its use has varied widely across Clinical Commissioning Groups. 
Further research has also suggested that uptake is suboptimal4,5. Indeed, 
internationally there is reported under use of anticoagulants 6,7,8 .  
 
A number of initiatives have been implemented to support oral anticoagulant 
uptake. Holt et al 9 developed and implemented a software tool used as part of the 
electronic health record system to improve anti-coagulation use. Using the software 
improved stroke and haemorrhage rates, but no significant change in prescribing 
was seen.  Adderley et al 10 explored whether the presence of contraindications to 
treatment influenced prescription. However, this had little influence on the decision 
to prescribe anticoagulants for the prevention of stroke in the UK and left many 
patients at risk of AF related stroke. 
 
To support the implementation of the NICE guidance, the West of England Academic 
Health Science Network (West of England AHSN)11 sought to bring together industry, 
Clinical Commissioning Groups and General Practitioners (GPs) to work 
collaboratively to secure practice change and improve patient outcomes. The Don’t 
Wait to Anti-coagulate quality improvement programme was established to enable 
this. A range of innovative interventions to support the implementation of the NICE 
guidance in primary care intervention was developed and piloted by the West of 
England AHSN. During the development phase (Phase 1) a series of interventions 
were piloted with 11 ‘Innovator Practices’ drawn from the seven Clinical 
Commissioning Groups. These interventions included education, training materials 
and patient decision aid tools. Using information gathered in Phase 1, the materials 
were refined for Phase 2 of the project. The quality improvement implementation 
methodology adapted the Institute for Healthcare Improvement Model12. 
 
The involvement of GPs in the quality improvement process is not without its 
challenges. The King’s Fund 13 has identified several barriers to quality improvement 
in general practice, such as GPs perceiving the ‘quality agenda’ as the domain of the 
practice manager, ambivalent attitudes to continual improvement, and a lack of a 
systems ‘mind-set’ (preferring autonomy). Additionally, there has been a reluctance 
to engage in a collective team approach, and a lack of skills in quality improvement 
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and change leadership13. Quality improvement support teams taking a more 
systems-based approach to planning, implementing and measuring the impact of 
evidence-based care have emerged to help practices implement quality 
improvement programmes. Here, the quality improvement team were employed in 
such a role to support the initiative and were keen to understand how the process 
worked and how a legacy of improvement could be supported. To achieve this, the 
realist evaluation aimed to identify whether the quality improvement process 
worked, determining how and in what circumstances.   
 
 
Methods  
 
A comprehensive evaluation was needed that would consider the implementation 
context and gather and analyse complex data from a number of general practices. 
The evaluation therefore employed a theory-based evaluation approach, that 
focused on the general practice context, the underpinning programme theory (which 
outlines why and how the quality improvement intervention leads to certain 
outcomes and the conditions in which this takes place)14 and used mixed-methods to 
test the programme theory.  
 
Evaluation environment 
 
The programme was implemented within one geographical region in the UK. In total, 
51 practices were involved in the overall project (n=61%).  The evaluation team 
concentrated on six GP practices selected from the 51. The sample size was based on 
Evans et al’s15 experience that six case studies provided sufficient data to examine 
regularities in context, mechanism and outcomes within a realist evaluation.  
 
Those practices involved ranged in list size and location as shown in Table 1.  
 
Table 1: General Practice Context 
 
General 
Practice Case 
study number 
Location Patient List Size 
(nearest 1,000) 
Pharmacy Support 
1 Small town 7000 Interface Clinical Services 
2 Town 12000 Practice based 
3 Small town 4000 Interface Clinical Services 
4 Town 9000 Practice based 
5 Small town 9000 Interface Clinical Services 
6 Town 10000 Practice based 
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The programme  
 
The programme was developed following initial pilot work in phase 1.  Clinical skills 
training for GPs and pharmacists was offered, along with information on atrial 
fibrillation management. Attendance at an initial training session was required prior 
to involvement.  A welcome pack for general practices including project information 
and posters to advertise the programme to patients. A programme website with 
information about treatment options and answers to frequently asked questions was 
available.  Training on the use of website resources was also accessible. Further 
online resources included patient information and a decision-making tool. Training in 
quality improvement methodology was also supplied for the practice. The quality 
improvement team offered regular reviews and telephone support throughout the 
lifespan of the project. 
 
A steering group for the project was in place which included representatives from 
industry, the Clinical Commissioning Group and the West of England AHSN. 
Importantly, a GP with special interest in cardiac care was involved in the steering 
group, developed and delivered the specialist training and provided ongoing support 
to the project. This role was funded as part of the project, alongside a project lead 
role, additional practice support pharmacy hours and the provision of interface 
clinical service pharmacists. Two members of the quality improvement team were 
also funded by the industry partners involved.  
 
All of the participating practices were offered support to complete an initial patient 
audit by the interface clinical services pharmacist. The purpose of the audit was to 
interrogate the GP clinical systems and produce a list of patients with a diagnosis of 
atrial fibrillation. This list was stratified to produce lists of patients for review as per 
NICE guidelines CG 180.  Following this initial stratification, a desktop assessment 
was undertaken first to determine which patients were suitable for a review by the 
GP, either face-to-face, on the telephone or in another way chosen by the practice. A 
meeting was facilitated to enable patient involvement in decision-making about 
ongoing prescription treatment, which was guided by tools available on the website.  
 
Realist evaluation 
 
Realist evaluation16 is a theory-driven, practice-orientated evaluation method based 
on case study, or close observation of a programme in ‘real life’ operation which, in 
this case, was the impact of the quality improvement process on anti-coagulant 
prescribing by local GPs.  
 
Realist evaluation tests a programme theory (a theoretical idea of how the 
programme is supposed to work) and considers what works for whom, in what 
circumstances, and why 16,17. Realist outcomes are understood through careful, 
systematic consideration of context, mechanism and outcome. Context (C) refers to 
anything external to the programme that might be acting as a barrier or facilitator to 
its implementation, or its intended effects. Mechanism (M) refers to the means of 
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achieving the desired outcome and focuses on identifying causal pathways, which 
are first hypothesised, then tested using qualitative methods to understand complex 
pathways or idiosyncrasies. Outcomes (O) are the intended and unintended 
consequences of a programme 18.  
 
Programme theory  
 
Hypothesizing the programme theory commenced with an initial review of the 
evidence supporting the intervention. Key to supporting the intervention were: the 
NICE guidance2, European Society of Cardiology: Guidelines for the Management of 
Atrial Fibrillation 19, and the Atrial Fibrillation Association: The Safe Report20. These 
provided the evidence base for best practice in the treatment of atrial fibrillation, 
leading to preventative prescribing, increased patient care, and improved resource 
use.  
 
The quality improvement project team identified three underlying theoretical 
frameworks supporting the programme theory: the model for improvement21, 
complexity and systems thinking22, and clinical microsystems theory23.  
 
The model for improvement aims to accelerate innovation adoption, working 
alongside existing change models, which in this case included the Plan Do Study Act 
(PDSA) cycle24. Complexity and change systems theory considers an organisation as a 
complex system composed of many components in frequent interaction. Within this 
programme the GP, pharmacist, quality improvement team members and patients 
would each have had a perspective of the system. Analysing these different 
perspectives enables understanding of the processes operating within the whole 
system. Clinical microsystems theory also takes a systems approach, but places the 
patient at the centre of a small, frontline network operating as part of a larger 
system. In this case, the practices and pharmacists participating in the intervention 
are viewed as a small team within the wider National Health Service (NHS).  
 
Drawing on best practice in the treatment of atrial fibrillation (including preventative 
prescribing, enhancing the patient experience and improving resource use), the 
following programme theory was devised: 
 
 
General practices have adopted a system for atrial fibrillation patient 
pathways that accords with the NICE guidance. The mechanisms that lead to 
the use of the system are part of a quality improvement process which 
includes training, information provision, and workload resources used by GPs 
who reason that it will help them to meet patient, surgery or personal goals.  
 
Supporting GP practices to identify the atrial fibrillation patient pathway as a 
system enables evidence- based change through that system. This leads to 
outcomes that include a review of oral anticoagulation prescribing, shared 
decision-making between GPs and patients, improved value and outcomes for 
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patients and the systems learning legacy is retained for future quality 
improvement programmes. 
 
 
The programme components and anticipated CMOs 
 
Following the literature and evidence reviews we sought clarification of our 
proposed theory areas and additional context, mechanism, outcome configurations 
through a focus group meeting with the quality improvement team, see Table 2.  
 
Insert Table 2 
 
Table 2. Theory areas and candidate CMOs for implementation. 
 
Theory Area Context Mechanism Outcome 
Model for 
improvement 
 
 
 
 
 
Complexity 
theory 
 
 
 
 
 
 
 
 
 
Microsystem 
GP practices with a 
quality improvement 
need for atrial 
fibrillation 
management.  
 
 
NICE guidance and 
other evidence. 
Collaborative West of 
England AHSNproject 
involving industry, 
commissioners and 
NHS. 
 
 
51 participating 
practices with a GP 
lead, pharmacist 
support, West of 
England AHSNproject 
team members 
involved. 
Plan Do Study Act 
cycle and quality 
improvement team 
are felt to meet that 
need. 
 
 
Initial data sets, phase 
1 evaluation, training, 
website, quality 
improvement team 
support role and 
workload resources 
lead GPs and 
pharmacists to reason 
that change is 
required.  
 
Access to expert 
support, resource to 
review prescribing 
data and 
implementation team 
visits to practices all 
make GPs feel they 
have enough support 
to bring about a 
change.   
 
Review of atrial 
fibrillation patients 
with ultimate 
reduction in strokes.  
 
 
 
Change in prescribing 
that meets the NICE 
guidance.  
 
 
 
 
 
 
 
 
Anti-coagulation 
prescribing reviewed. 
Shared decision 
making between GPs 
and patients. Legacy of 
quality improvement. 
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Data collection methods 
 
 
Ethical approvals were secured from the University ethics committee. This preceded 
qualitative data collection in the practices, which was completed with informed 
consent in place for those individuals involved.  
 
Observations 
 
The evaluation team members attended the practice based meetings between the 
quality improvement team and the practice lead GP and in case study site 2, the 
pharmacist was also present.  These meetings were scheduled to occur at three 
stages: the initial planning meeting, followed by review and concluding meetings. 
The main content of the meeting was noted, particularly considering the quality 
improvement implementation. Notes were made relating to the context and 
mechanisms that might have impacted on the experience. For example, references 
to the use of training materials and resources, specialist support, quality 
improvement team support and anything related to the practice context such as 
workload.   
 
Interviews 
 
Individual interviews were completed with GP practice leads regarding what had 
‘worked well’ in the quality improvement process, using the context, mechanism and 
outcome hypothesis as a framework. The GPs were selected as they had led the 
implementation in the practices and had been involved with the quality 
improvement process. In case study site 2, the pharmacist had also been very closely 
involved and was therefore part of the observation and interview process.   In total 
17 interviews took place (see Table 3), providing rich data about the quality 
improvement implementation process.  
 
Table 3:  Interviews conducted per case study per round 
 
 
 
Case study 
First round 
interviews 
Second round 
interviews 
Final interviews Total 
Interviews 
 
1 1 GP 1 GP 1 GP 3 
2 
1 GP  
 1 Pharmacist 0 
1 GP  
1 Pharmacist 4 
3 1 GP 1 GP 1 GP 3 
4 1 GP 1 GP 1GP 3 
5 1 GP 1 GP 1 GP 3 
6 0 0 1 GP 1 
Total 6 4 7 17 
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Recruitment process and sampling strategy. 
 
 
The  project encompassed six GP practices within one clinical commissioning group 
area, based on Evans et al’s15 experience that six case studies provided sufficient 
data to examine CMO regularities. The initial aim was to select a range of different 
sized practices, including rural and urban catchment areas. However, in effect, the 
sample was a self-selecting convenience sample, being those practices who agreed 
to participate when approached by the West of England AHSNvia email. Overall, 61% 
of practices in the region were involved (n=51) and the evaluation proceeded with 
six of these.   
 
Data analysis 
 
Realist evaluation analyses the data in the form of configuration patterns of context, 
mechanism and outcome16.  These patterns represent the causal pathways, where 
mechanisms and context are seen to relate to outcomes. The realist evaluation tests 
and refines the programme theory developed initially. To achieve this the evaluation 
analysed the data through identifying context, mechanism and outcome 
configurations based on the initial programme theory.   
 
Interviews were audio-recorded and transcripts were subjected to a coding and 
memo-writing process25, along with the observational data recorded at the practice 
meetings. In coding, specific aspects of the context and mechanism and outcomes of 
the quality improvement process, as it unfolded in each practice, were identified. 
Initially, members of the team undertook an analysis of the transcriptions related to 
interviews and observation they had undertaken. These data were also coded 
independently by a second team member and the two sets of analysis were 
reviewed, developing one set of data for each practice. These were presented as the 
context, mechanism, and outcome configurations for the practice.   
 
Refining the programme theory  
 
The initial programme theories were compared and contrasted with the findings 
from GP and pharmacist interviews and observations in the six GP practices. This 
comparison was used to refine the theory and new mechanisms and patterns were 
identified.  
 
 
Results 
 
Theory area: Model for improvement 
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In terms of context, all the GPs worked within the project’s collaborative framework, 
engaging through the quality improvement team with industry and commissioning. 
Additionally, one practice was already reviewing their prescriptions as a result of 
their NHS accountability. 
 
Some GPs were aware of the NICE guidance and wider evidence for the prescribing 
review.  One GP acknowledged their accountability thus,  
 
“It’s part of clinical governance…and I think it’s an important part of 
everyone’s working, continually developing…services, making sure that the 
services we offer are kept to a high standard…The NHS is accountable for that 
and part of the accountability is making sure you regularly do auditing, 
quality improvement projects.” (GP CS2) 
 
However, one GP noted,  
  
“the workload that doctors and GP staff experience is rising…and it was 
sometimes difficult to allocate time…to focus on the project.” (GP CS4) 
 
As a consequence, mechanisms that allowed the practices to flexibly implement the 
programme and achieve the outcomes were adopted. These included aspects such 
as being able to determine when to start the programme, ways of engaging with the 
quality improvement team and using online materials when needed.  
 
The training provision was valued by all GP participants and positively noted by 
those pharmacists who attended. The website resources were used variably with 
practitioners engaging to greater or lesser extents.  
 
 The six GP practices reported changes in prescribing practice and data supporting 
this was collected by the quality improvement team as part of a wider quality 
improvement evaluation.  
 
As shown in Table 4, the initial theory model for improvement did take account of 
the range of practice settings all starting at different points and with different 
contextual issues.   
 
Table 4. CMOs for model for improvement 
 
Context Mechanism Outcome 
Practice implemented early. 
(CS3) 
 
Workload, time and 
paperwork pressures at 
practices. (CS4&5) 
 
 
Quality improvement team 
support not needed. 
 
One delayed for 3 months. 
One focused on high risk 
patients. 
 
 
Atrial fibrillation review 
legacy in place. 
 
One practice quickly 
identified patients for 
review. At one, Pharmacist 
and GP shared review. GP 
felt argument for prescribing 
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Audit review process in 
place, but not all patients 
captured. (CS1) 
 
 
Some improvement support 
and tools used. 
NOACs strengthened.  
 
Reviewed 40 patients. 
 
 
 
Theory area: Complexity theory 
 
When reviewing the findings it was clear that complexity theory does not take 
account of established pre-conceived ideas, held in one part of the system, of those 
in other parts. For example, one GP indicated that they deliberately avoided 
interactions with pharma, saying, 
  
“And you know we try not to see drug reps here, because it’s very easy to 
alter your prescribing.” (GP, CS1) 
 
The initial theory had assumed that bringing a collaboration of industry, 
commissioning and the NHS would achieve a change in prescribing, without fully 
appreciating the impact of previous learned routines and pre-conceptions.  
 
Table 5 shows the extent to which accountability to external bodies provided 
effective motivation for practices. This new understanding should be encompassed 
into the theory.  
 
Table 5. CMOs for complexity theory 
 
Context Mechanism Outcome 
GP accountability to NHS 
clinical governance 
standards acknowledged. 
(CS5) 
 
Practice partners 
encouraged to engage. 
Completed the project. 
New protocols in place. 
 
Theory area: Microsystem theory 
 
The initial Microsystem theory has provided a way of understanding the importance 
of the local general practice context and the provision of key mechanisms in 
achieving the outcomes. Where the lead GP lacked experience or resources, the 
quality improvement programme provided essential mechanisms such as training, 
networking and materials to ensure that the prescribing review was achieved. For 
example, one newly appointed GP said,  
 
“I wasn’t sure what would be suitable for our surgery…and I approached 
several people during that training to understand elements of this project and 
how it would be suitable for our practice.” (GP CS5) 
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Interestingly, where key motivators were in place, such as prior experience and a 
commitment to quality improvement and research based practice, the programme 
achieved optimal outcomes such as an efficient prescribing review, completed with 
patient involvement and a lasting QI legacy (see Table 6). For example, the 
pharmacist at one such practice said,  
 
“they are open to best practice and change and a good clinical team here as 
there is no resistance to change.” (Pharmacist, CS2) 
 
 
Table 6. CMOs for microsystem theory 
 
Context Mechanisms Outcome 
GPs with an interest in 
cardiovascular disease or 
personal experience. (CS2&3) 
 
 
 
 
 
 
Research based practice 
focused on quality patient care. 
(CS2) 
 
 
 
 
New GP, no AF nurse, or 
pharmacist (CS1&5). Not 
familiar with audit process. 
 
 
 
 
 
GP has trusting relationship 
with patient. (CS6) 
 
GP commitment meant they 
attended training, drove 
improvement process 
through, and went through 
website with patients.  
 
 
 
 
Research interest prompted 
training to be disseminated 
to the team, project 
responsibilities to be shares 
and a system of pharmacy 
review developed. 
 
GP uncertainty meant 
reliance on training materials 
and website. Additional 
training. 
Spoke to other GPs. Shared 
review with other GPs at 
practice.  
 
Consultation over the phone 
and patient trust in their GP. 
Reviewed audit and changed 
patients before project start. 
Used website risk 
assessment. Legacy of 
annual review in 
development. Plan quality 
improvement process for 
other conditions.  
 
Prevention of errors. Face to 
face consultations. Patients 
confident to change.  
 
 
 
 
Explained risk assessments 
to patients. Reviewed all 
patients. Intend to use 
improvement process again. 
Two-way decision-making 
process with patients.  
 
 
Medication changed. 
Workload minimized.  
 
 
 
Discussion  
 
There are a number of challenges to implementing NICE guidance within GP 
settings13. The West of England AHSNused a quality improvement process12 and 
PDSA cycles24 to support change implementation, uniquely bringing together key 
industry, commissioners and GP stakeholders to support a review of anti-coagulation 
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prescribing. A realist evaluation was able to show whether and how the 
implementation of a quality improvement process in general practices worked.  
 
Many practices completed a review of anticoagulation prescribing, making 
prescription changes with patient involvement in decision-making seen to varying 
degrees. In some cases, a quality improvement legacy was also seen, with a number 
of GPs seeking to use the approach in the future.  The evaluation was also able to 
provide learning about the use of a quality improvement process for the West of 
England AHSN, demonstrating that certain mechanisms and contexts are important 
in achieving desired outcomes. In particular, providing training, support and having 
keen and enthusiastic local expertise involved in the delivery was critical.  
 
In considering the findings more fully, it must be noted that there were some 
limitations in the evaluation. The six practices taking part in the study were self-
selecting, agreeing to take part following an invitation from theWest of England 
AHSN.  This recruitment approach can preference the selection of those with a more 
positive stance and should be considered as potentially limiting the validity of the 
study. It should also be noted that significant resource was made available to the 
practices involved through the provision of the quality improvement team support 
and the additional training and website materials, which is not generally available. 
 
 
It was clear that the model for improvement12 used by the Academic Health Science 
Network allowed flexible implementation of the programme, which achieved some 
intended outcomes. In particular, the review of patient prescription was completed, 
and a change of prescribing practice was seen. However, the local context of the 
practice was an important factor in securing desired outcomes and changes in 
prescribing. Where GPs had personal experience or expertise in the area this aided 
motivation to change and greater engagement with the project was seen. In these 
cases there were reports of patient engagement in the change process and evidence 
of system review being implemented. However, where practices felt that their 
approach was already good enough, then there was limited engagement with the 
support in all its forms.  
 
There was also evidence of some practices adopting the improvement process, with 
intention to use it as part of ongoing quality improvement activity. This was 
particularly the case in those practices where GPs had more experience in atrial 
fibrillation, engaged fully with the quality improvement project and took an active 
role in research.  This suggests securing a quality improvement legacy is more likely 
in those practice areas fully engaging in the initial project processes.  
 
The resources provided by the project were also valuable mechanisms in supporting 
the achievement of outcomes. Of particular note, the training provided by a GP, who 
had expertise as a cardiac specialist and passion for the subject, was highly valued. 
Some GPs were naturally suspicious about the future potential for working together 
in partnership with the pharmaceutical industry (who are viewed as profit driven). 
The partnership was challenging perceptions that pharma and the NHS hold 
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opposing positions, the NHS having a business model that strives to put patients’ 
first27. The clear enthusiasm and belief in the benefits of change held by the GP 
trainer convinced those attending that they could and should act to deliver the 
project. The joint steering group was also an important mechanism in challenging 
long-held GP views. Through this unique working relationship, it became clear that 
all parties were working to secure better patient outcomes and a common goal.    
The website materials produced were helpful to some practices.   They were most 
often used by those GPs with less experience and interest in atrial fibrillation, who 
engaged with the range of information and support tools provided.  
 
 
Some practices were already engaged with the NICE guidelines2, and had their own 
systems in place for reviewing and following up patients with atrial fibrillation, whilst 
others did not. This correlates with The King’s Fund finding13  that some GPs may 
lack a systems ‘mind-set’, and do not have any formal system in place that will 
enable them to track/monitor patients. As GP practices often work in isolation, a co-
ordinated project that included the provision of training, additional support from the 
quality improvement team and provided highly valued link pharmacists, enabled 
them to network with each other and share best practice. The provision of such 
support has seemingly overcome a lack of quality improvement skills and leadership 
that has been seen to impact on the delivery of quality improvement in general 
practice13. 
 
 
In conclusion, it is clear that the quality improvement approach has secured the 
review of prescriptions and changes in patient medication, which has seen the 
implementation of the NICE guidelines 2 across six general practices. The key 
mechanism to adopting the NICE guidelines2 in GP practices was their access to 
additional expert support and training (provided during the programme). In addition 
to working in close partnership with the quality improvement team, during a process 
of education, self-analysis/reflection on existing practice, improvement and change; 
this gave rise to a greater understanding of the QI process for improving the 
outcomes for patients with atrial fibrillation. 
 
To support quality improvement, which aims to secure practice change and deliver a 
quality improvement legacy, the mechanisms of a team, training and resource 
provision are helpful. It is also apparent that the use of a model for improvement 
that allows flexibility in implementation and takes account of local practice context 
should be encouraged.  
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